IN2014CN04055A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04055A IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
- Authority
- IN
- India
- Prior art keywords
- proportion
- composition
- increased
- disease
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001657523 Coriobacteriaceae Species 0.000 abstract 1
- 241001608234 Faecalibacterium Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 241001430183 Veillonellaceae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555800P | 2011-11-04 | 2011-11-04 | |
| PCT/US2012/063008 WO2013067146A1 (en) | 2011-11-04 | 2012-11-01 | Methods and compositions for modulating gastrointestinal bacteria to promote health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04055A true IN2014CN04055A (cg-RX-API-DMAC7.html) | 2015-10-23 |
Family
ID=48192757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4055CHN2014 IN2014CN04055A (cg-RX-API-DMAC7.html) | 2011-11-04 | 2012-11-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150209383A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2773357A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014532710A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140093252A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104159588A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012332491A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014010660A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854398A1 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014CN04055A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014005433A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013067146A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312713D0 (en) * | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3283087A4 (en) * | 2015-04-14 | 2019-03-13 | Ubiome Inc. | METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| CN106994136A (zh) * | 2016-01-26 | 2017-08-01 | 富士胶片株式会社 | 肠内细菌数量抑制剂、食品、及药品 |
| SG11201807616RA (en) * | 2016-03-14 | 2018-10-30 | B Food Science Co Ltd | Proliferative agent for faecalibacterium |
| EP3511406A4 (en) * | 2016-09-06 | 2020-04-01 | BGI Shenzhen | FAECALIBACTERIUM LONGUM AND APPLICATION THEREOF |
| EP3630146A1 (en) | 2017-06-02 | 2020-04-08 | Goodgut S.L. | Grape skin for use in the treatment of dysbiosis |
| AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| EP3466417A1 (en) * | 2017-10-04 | 2019-04-10 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| CN109998112B (zh) * | 2017-12-22 | 2024-05-14 | 奥地利商艾尔柏有限公司 | 红蝽杆菌纲促进肠道健康的用途 |
| EP3752167A1 (en) * | 2018-02-14 | 2020-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polydextrose for the treatment of inflammatory diseases |
| EP3790997A4 (en) * | 2018-05-09 | 2022-03-16 | Carbiotix AB | METHOD FOR MEASURING AND IMPROVING INTESTINAL HEALTH |
| US11376289B2 (en) | 2018-05-31 | 2022-07-05 | Bgi Shenzhen | Composition and uses thereof |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
| EP4041264A1 (en) * | 2019-10-07 | 2022-08-17 | Siolta Therapeutics, Inc. | Therapeutic pharmaceutical compositions |
| KR102174095B1 (ko) * | 2019-12-11 | 2020-11-05 | 주식회사 에이치이엠 | 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 |
| WO2021184008A1 (en) * | 2020-03-13 | 2021-09-16 | Fitbiomics Inc. | Probiotic compositions for improving human health and athletic performance |
| JP2021168651A (ja) * | 2020-04-16 | 2021-10-28 | サンスター株式会社 | フィーカリバクテリウム属細菌増殖用組成物、酪酸産生増加用組成物、及び腸内環境改善用組成物 |
| JP2024518270A (ja) * | 2021-05-06 | 2024-05-01 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 |
| WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0394655A (ja) * | 1989-09-06 | 1991-04-19 | Otsuka Pharmaceut Co Ltd | 栄養補給用組成物 |
| JP4328473B2 (ja) * | 2001-04-09 | 2009-09-09 | 雪印乳業株式会社 | 肥満予防改善飲食品 |
| FI20020078A7 (fi) * | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| JP2003334025A (ja) * | 2002-05-15 | 2003-11-25 | Toyo Shinyaku:Kk | 健康食品 |
| JP2005534315A (ja) * | 2002-08-06 | 2005-11-17 | ダニスコ エイ／エス | 食品および薬学的組成物中に細胞外多糖類を産生する乳酸桿菌の使用 |
| GB0302872D0 (en) * | 2003-02-10 | 2003-03-12 | Univ Liverpool | Treatment of inflammatory bowel disease |
| US20080292766A1 (en) * | 2007-05-23 | 2008-11-27 | Hoffman Andrew J | Edible Composition Comprising a Slowly Digestible or Digestion Resistant Oligosaccharide Composition |
| GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| US8816067B2 (en) * | 2009-05-07 | 2014-08-26 | Tate & Lyle Ingredients France SAS | Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans |
-
2012
- 2012-11-01 MX MX2014005433A patent/MX2014005433A/es not_active Application Discontinuation
- 2012-11-01 BR BR112014010660A patent/BR112014010660A2/pt not_active IP Right Cessation
- 2012-11-01 IN IN4055CHN2014 patent/IN2014CN04055A/en unknown
- 2012-11-01 CA CA2854398A patent/CA2854398A1/en not_active Abandoned
- 2012-11-01 KR KR1020147014663A patent/KR20140093252A/ko not_active Withdrawn
- 2012-11-01 WO PCT/US2012/063008 patent/WO2013067146A1/en not_active Ceased
- 2012-11-01 US US14/355,963 patent/US20150209383A1/en not_active Abandoned
- 2012-11-01 AU AU2012332491A patent/AU2012332491A1/en not_active Abandoned
- 2012-11-01 CN CN201280064861.5A patent/CN104159588A/zh active Pending
- 2012-11-01 EP EP12845672.0A patent/EP2773357A4/en not_active Withdrawn
- 2012-11-01 JP JP2014540070A patent/JP2014532710A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104159588A (zh) | 2014-11-19 |
| EP2773357A1 (en) | 2014-09-10 |
| WO2013067146A1 (en) | 2013-05-10 |
| AU2012332491A1 (en) | 2014-05-29 |
| JP2014532710A (ja) | 2014-12-08 |
| EP2773357A4 (en) | 2015-08-26 |
| BR112014010660A2 (pt) | 2017-05-09 |
| CA2854398A1 (en) | 2013-05-10 |
| MX2014005433A (es) | 2014-08-22 |
| US20150209383A1 (en) | 2015-07-30 |
| KR20140093252A (ko) | 2014-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04055A (cg-RX-API-DMAC7.html) | ||
| Zou et al. | Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice | |
| Li et al. | Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice | |
| Yuan et al. | Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice | |
| Jiao et al. | Blueberry polyphenols extract as a potential prebiotic with anti-obesity effects on C57BL/6 J mice by modulating the gut microbiota | |
| Quezada et al. | Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics | |
| Zhang et al. | Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha | |
| Shang et al. | Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes | |
| Ge et al. | Effect of industrial trans-fatty acids-enriched diet on gut microbiota of C57BL/6 mice | |
| Fan et al. | Research progress of gut microbiota and obesity caused by high-fat diet | |
| Chen et al. | Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet | |
| Zhou et al. | Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring | |
| Deng et al. | Hypoglycemic effects of different molecular weight konjac glucomannans via intestinal microbiota and SCFAs mediated mechanism | |
| JP2015523362A5 (cg-RX-API-DMAC7.html) | ||
| WO2011097273A8 (en) | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine | |
| Kobyliak et al. | Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention | |
| Deng et al. | Shatianyu (Citrus grandis L. Osbeck) flavonoids and dietary fiber in combination are more effective than individually in alleviating high-fat-diet-induced hyperlipidemia in mice by altering gut microbiota | |
| Wan et al. | The impact of dietary sn-2 palmitic triacylglycerols in combination with docosahexaenoic acid or arachidonic acid on lipid metabolism and host faecal microbiota composition in Sprague Dawley rats | |
| WO2010136900A3 (en) | Methods of using krill oil to treat risk factors for metabolic disorders and obesity | |
| RU2014153787A (ru) | Лечение и профилактика сердечно-сосудистого заболевания и тромбоза | |
| Aoki et al. | Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice | |
| Villamil et al. | Adverse effect of early-life high-fat/high-carbohydrate (“Western”) diet on bacterial community in the distal bowel of mice | |
| Yang et al. | Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora | |
| Liu et al. | Salidroside protects mice from high-fat diet-induced obesity by modulating the gut microbiota | |
| Aldamarany et al. | Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet |